Marcain Polyamp Steripack 0.5%

  • Name:

    Marcain Polyamp Steripack 0.5%

  • Company:
    info
  • Active Ingredients:

    Bupivacaine hydrochloride anhydrous

  • Legal Category:

    Product subject to medical prescription which may not be renewed (A)

Patient Information Leaflet Patient Information Leaflet last updated on medicines.ie: 20/09/17

files-icon(Click to Download)

XPIL

Summary of Product Characteristics last updated on medicines.ie: 21/9/2017
print

Print ViewKeyword Search SmPC

Aspen

Aspen

Company Products

Medicine NameActive Ingredients
Medicine Name Aldomet Tablets 250 mg Active Ingredients Methyldopa
Medicine Name Aldomet tablets 500 mg Active Ingredients Methyldopa
Medicine Name Alkeran 2 mg Film-coated Tablets Active Ingredients Melphalan
Medicine Name Alkeran 50 mg, Powder and Solvent for Solution for Infusion Active Ingredients Melphalan
Medicine Name Anectine 50 mg/ml Solution for Injection or Infusion Active Ingredients Suxamethonium Chloride
Medicine Name Arixtra Fondaparinux sodium solution for injection 1,5 mg/ 0,3 ml Active Ingredients Fondaparinux sodium
Medicine Name Arixtra Fondaparinux sodium solution for injection 10 mg/ 0,8 ml Active Ingredients Fondaparinux sodium
Medicine Name Arixtra Fondaparinux sodium solution for injection 2,5 mg/ 0,5 ml Active Ingredients Fondaparinux sodium
Medicine Name Arixtra Fondaparinux sodium solution for injection 5 mg/ 0,4 ml Active Ingredients Fondaparinux sodium
Medicine Name Arixtra Fondaparinux sodium solution for injection 7,5 mg/ 0,6 ml Active Ingredients Fondaparinux sodium
Medicine Name Dexamethasone 2mg Tablets Active Ingredients Dexamethasone
Medicine Name Diprivan 1% w/v Emulsion for Injection or Infusion, Pre-filled Syringe (50ml) Active Ingredients Propofol
Medicine Name Emla Cream 5% Active Ingredients Lidocaine, Prilocaine
Medicine Name Fludrocortisone acetate 0.1mg Tablets Active Ingredients Fludrocortisone Acetate
Medicine Name Imuran Powder for Solution for Injection or Infusion 50mg Active Ingredients azathioprine sodium
Medicine Name Imuran Tablets 25mg Active Ingredients Azathioprine
Medicine Name Imuran Tablets 50mg Active Ingredients Azathioprine
Medicine Name Kemadrin Tablets Active Ingredients Procyclidine Hydrochloride
Medicine Name Lanoxin 250 microgram tablets Active Ingredients Digoxin
Medicine Name Lanoxin Injection Active Ingredients Digoxin
Medicine Name Lanoxin PG 50 micrograms/ml Elixir Active Ingredients Digoxin
Medicine Name Lanoxin PG Tablets Active Ingredients Digoxin
Medicine Name Lanvis 40 mg tablets Active Ingredients Tioguanine
Medicine Name Leukeran 2mg Film-coated Tablets Active Ingredients Chlorambucil
Medicine Name Marcain 0.25% with Adrenaline (5 micrograms per ml) 1:200,000 Active Ingredients Adrenaline tartrate, Bupivacaine Hydrochloride
1 - 0 of 63 items.Total: Infinity pages

When a pharmaceutical company changes any document, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.

Updated on 21 September 2017 SmPC

Reasons for updating

  • New SmPC for new product

Legal category: Product subject to medical prescription which may not be renewed (A)

Updated on 21 September 2017 SmPC

Reasons for updating

  • Change to section 6.6 - Special precautions for disposal and other handling
  • Change to section 7 - Marketing authorisation holder
  • Change to section 8 - Marketing authorisation number(s)
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Text in red = new text
Text strikethrough = deleted text

 

 

6.6     Special precautions for disposal of a used medicinal product or waste materials derived from such medicinal product and other handling of the product

Marketing Authorisation holder

Aspen Pharma Trading Limited,

3016 Lake Drive,

Citywest Business Campus,

Dublin 24,

Ireland.

 

AstraZeneca UK Ltd.,

600 Capability Green,

Luton,

 

Marketing authorisation number(s)

PA 1691/024/002

PA 970/45/2

 

Date of revision of the text

September 2017

21 Oct 2016

 

 

 

Updated on 20 September 2017 PIL

Reasons for updating

  • New PIL for new product

Updated on 20 September 2017 PIL

Reasons for updating

  • Change to section 6 - marketing authorisation holder
  • Change to section 6 - marketing authorisation number
  • Change to section 6 - date of revision

Updated on 8 November 2016 SmPC

Reasons for updating

  • New individual SPC (was previously included in combined SPC)

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Joint SmPC changed to individual SmPCs, changes for this strength from joint SmPC are as follows:

 

Section 4.2: editorial update to dosage recommendation for children table.

Section 4.4: updated with information in relation to hypotension and bradycardia.

Section 10: updated date of revision

Updated on 8 June 2015 PIL

Reasons for updating

  • Change to date of revision
  • Change to improve clarity and readability
  • Addition of information on reporting a side effect.

Updated on 29 August 2013 PIL

Reasons for updating

  • Change to warnings or special precautions for use
  • Change to side-effects
  • Change to date of revision
  • Change to dosage and administration
  • Addition of information on reporting a side effect.

Updated on 4 November 2011 PIL

Reasons for updating

  • Change to storage instructions
  • Change to further information section
  • Change to date of revision
  • Introduction of new pack/pack size

Updated on 22 April 2010 PIL

Reasons for updating

  • Change to warnings or special precautions for use
  • Change due to user-testing of patient information

Updated on 25 July 2006 PIL

Reasons for updating

  • Change to warnings or special precautions for use
  • Change to instructions about overdose
  • Change to side-effects
  • Change to date of revision

Updated on 24 October 2005 PIL

Reasons for updating

  • Change to warnings or special precautions for use
  • Change of contraindications
  • Change to instructions about overdose
  • Change to drug interactions
  • Change to information about driving or using machinery
  • Change to date of revision
  • Change to information about pregnancy or lactation
  • Change to dosage and administration

Updated on 28 July 2004 PIL

Reasons for updating

  • New PIL for medicines.ie